Henry Ford Health

Henry Ford Health Scholarly Commons
Diagnostic Radiology Articles

Diagnostic Radiology

1-1-2019

Volumetric and Voxel-Wise Analysis of Dominant Intraprostatic
Lesions on Multiparametric MRI
James Lee
Henry Ford Health, JLee24@hfhs.org

Eric Carver
Henry Ford Health, ecarver1@hfhs.org

Aharon Feldman
Henry Ford Health, afeldma2@hfhs.org

Milan Pantelic
Henry Ford Health, milan@rad.hfh.edu

Mohamed A. Elshaikh
Henry Ford Health, MELSHAI1@hfhs.org

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/radiology_articles

Recommended Citation
Lee J, Carver E, Feldman A, Pantelic MV, Elshaikh M, and Wen N. Volumetric and Voxel-Wise Analysis of
Dominant Intraprostatic Lesions on Multiparametric MRI. Front Oncol 2019; 9:616.

This Article is brought to you for free and open access by the Diagnostic Radiology at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Diagnostic Radiology Articles by an authorized administrator of
Henry Ford Health Scholarly Commons.

Authors
James Lee, Eric Carver, Aharon Feldman, Milan Pantelic, Mohamed A. Elshaikh, and Ning Wen

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
radiology_articles/174

ORIGINAL RESEARCH
published: 05 July 2019
doi: 10.3389/fonc.2019.00616

Volumetric and Voxel-Wise Analysis
of Dominant Intraprostatic Lesions
on Multiparametric MRI
Joon Lee 1 , Eric Carver 1 , Aharon Feldman 1 , Milan V. Pantelic 2 , Mohamed Elshaikh 1 and
Ning Wen 1*
1

Department of Radiation Oncology, Henry Ford Health System, Detroit, MI, United States, 2 Department of Radiology, Henry
Ford Health System, Detroit, MI, United States

Introduction: Multiparametric MR imaging (mpMRI) has shown promising results in the
diagnosis and localization of prostate cancer. Furthermore, mpMRI may play an important
role in identifying the dominant intraprostatic lesion (DIL) for radiotherapy boost. We
sought to investigate the level of correlation between dominant tumor foci contoured
on various mpMRI sequences.
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Methods: mpMRI data from 90 patients with MR-guided biopsy-proven prostate cancer
were obtained from the SPIE-AAPM-NCI Prostate MR Classification Challenge. Each
case consisted of T2-weighted (T2W), apparent diffusion coefficient (ADC), and Ktrans
images computed from dynamic contrast-enhanced sequences. All image sets were
rigidly co-registered, and the dominant tumor foci were identified and contoured for each
MRI sequence. Hausdorff distance (HD), mean distance to agreement (MDA), and Dice
and Jaccard coefficients were calculated between the contours for each pair of MRI
sequences (i.e., T2 vs. ADC, T2 vs. Ktrans , and ADC vs. Ktrans ). The voxel wise spearman
correlation was also obtained between these image pairs.
Results: The DILs were located in the anterior fibromuscular stroma, central zone,
peripheral zone, and transition zone in 35.2, 5.6, 32.4, and 25.4% of patients,
respectively. Gleason grade groups 1–5 represented 29.6, 40.8, 15.5, and 14.1% of
the study population, respectively (with group grades 4 and 5 analyzed together). The
mean contour volumes for the T2W images, and the ADC and Ktrans maps were 2.14
± 2.1, 2.22 ± 2.2, and 1.84 ± 1.5 mL, respectively. Ktrans values were indistinguishable
between cancerous regions and the rest of prostatic regions for 19 patients. The Dice
coefficient and Jaccard index were 0.74 ± 0.13, 0.60 ± 0.15 for T2W-ADC and 0.61 ±
0.16, 0.46 ± 0.16 for T2W-Ktrans . The voxel-based Spearman correlations were 0.20 ±
0.20 for T2W-ADC and 0.13 ± 0.25 for T2W-Ktrans .
Conclusions: The DIL contoured on T2W images had a high level of agreement with
those contoured on ADC maps, but there was little to no quantitative correlation of these
results with tumor location and Gleason grade group. Technical hurdles are yet to be
solved for precision radiotherapy to target the DILs based on physiological imaging. A
Boolean sum volume (BSV) incorporating all available MR sequences may be reasonable
in delineating the DIL boost volume.
Keywords: prostate cancer, multiparametric MR, dominant intraprostatic lesions, tumor delineation, radiotherapy
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INTRODUCTION

coil. Each dataset consisted of T2W, ADC, and volume transfer
coefficient (Ktrans ) images computed from DCE sequences.
The T2W images were acquired using a turbo spin echo
sequence (TE/TR: 5,660/104 ms, Flip Angle: 90◦ with image
resolution of 0.5 × 0.5 × 3.0 mm3 ). The DWI was acquired
with a single-shot echo planar imaging sequence with diffusionencoding gradients in three directions (TR/TE: 2,700/63 ms, with
image resolution of 2.0 × 2.0 × 3.0 mm3 ). The ADC map was
calculated from three b-values of 50, 400, and 800 s/mm2 .The
DCE series were acquired using a 3-D turbo flash gradient echo
sequence (TR/TE: 3.4/1.5 ms, with image resolution of 1.5 × 1.5
× 3.0 mm3 and a temporal resolution of 3.5 s). The standard
Tofts model was used for pharmacokinetic modeling of the
contrast concentration curves. An automated reference tissue
method was used to estimate the arterial input function (25). The
transfer constant (Ktrans ) parametric maps were calculated from
the contrast concentration curves.
An experienced radiologist annotated suspicious lesions on
each MR modality, and MRI-guided biopsies were performed
to confirm the aggressiveness of the disease (i.e., Gleason grade
grouping). The tissue specimens were examined by expert
pathologists and the results were defined as the ground truth
in this study. Both the ADC and Ktrans image sets were rigidly
co-registered and resampled using linear interpolation to match
those of the T2W images. For example, resampling transformed
the resolution from 2.0 × 2.0 × 3.0 mm (ADC) and 1.5 × 1.5 ×
3.0 mm (Ktrans ) to 0.5 × 0.5 × 3.0 mm (T2W). The intraprostatic
lesions were then identified and contoured on each MR sequence
separately for every patient by a radiation oncologist based on the
radiologist’s annotation following criteria of hypointense values
on the T2W images (window 718, level 360) and ADC maps
(window 3,000, level 1,500) and high values on the Ktrans maps
(window 39, level 21). The DIL was separately contoured by
a second radiation oncologist for a subset of MR images (19
patients) to assess for interobserver variability. Representative
images of an intraprostatic lesion contoured on an ADC map,
Ktrans map and T2W image are shown in Figure 1.
The anatomic location of the intraprostatic lesions as well as
their corresponding Gleason grade group (1–5) were available for
each patient. Due to the small number of data points available,
Gleason grade groups 4 and 5 were analyzed together. To evaluate
the quantitative correlation between contours on each imaging
modality and its statistical dependence on tumor location and
Gleason grade group, the 95 percentiles of Hausdorff distance
(HD), mean distance to agreement (MDA), Dice coefficient, and
Jaccard index were calculated between the contours for each pair
of MR sequences (i.e., T2W vs. ADC, T2W vs. Ktrans , and ADC
vs. Ktrans ). These variables are defined in Table 1.
For the voxel-wise analysis, a Boolean sum volume (BSV) was
defined as a combination of the contours from all three image
modalities for each patient. This additional step was performed
to ensure that an equal number of representative voxels from
each MR sequence were included in the analysis. Fractional ranks
were then obtained for each voxel of the BSV and the Spearman
correlation was calculated. It is worth noting that the Spearman
correlation was selected because a monotonic relationship was
assumed between each pair of contours, as opposed to a linear

Prostate cancer is the most common malignancy of men in
the U.S., with an annual incidence of 161,360 cases resulting
in 26,730 deaths (1). Most patients are diagnosed with disease
localized to the prostate, for which radiation therapy is an
important curative treatment modality.
In the modern era of dose-escalated radiation therapy, the
entire prostate gland is treated to the same dose of radiation
irrespective of the biopsy-proven region of disease. Multiple
randomized studies have demonstrated that dose-escalation
improves biochemical progression-free survival (2, 3). It has also
been reported that local recurrences are dose-dependent and
most frequently occur at the site of the dominant intraprostatic
lesion (DIL) (4, 5)—defined as the most prominent cancerous
lesion within the prostate which also exhibits the most aggressive
clinical behavior. Numerous studies have suggested that the
addition of a boost to the DIL is safe and efficacious without
increased acute or late toxicity (6–14).
Multiparametric magnetic resonance imaging (mpMRI) is
rapidly becoming the standard diagnostic imaging modality for
prostate cancer. mpMRI can be defined as any functional form
of MR imaging which supplements standard anatomical T1(T1W) and T2-weighted (T2W) MR sequences. Namely, this
includes diffusion-weighted imaging (DWI), which measures the
Brownian motion of water molecules in tissue; dynamic contrastenhanced (DCE) sequences, which assess tumor angiogenesis
and detect microvascular vessel wall permeability; and MR
spectroscopy (MRS), which analyzes the chemical composition
of prostatic tissue, and compares it to that of cancerous tissue.
mpMRI has shown potential to increase the accuracy of tumor
detection, localization, and characterization of prostate cancer
(15–18). It has been demonstrated to have a negative predictive
value of up to 95% for clinically significant prostate cancer
(defined as the presence of Gleason pattern 4 or greater) (19, 20).
Whole amount histopathology has been used a gold standard
reference to evaluate DIL detection and localization accuracy
using mpMRI (21).
The correlation of tumor volume defined by pathology and
mpMRI was also investigated and it showed strong dependence
on both imaging techniques and specimen processing workflow
(22). There are still lack of studies to investigate whether a specific
MR sequence is optimal or if a combination of MR sequences
is mandatory in accurately delineating the DIL for radiotherapy
planning. In this study, we performed volumetric and voxel-wise
analyses of tumor foci delineated in three MR sequences and
report the level of concordance between them. Furthermore, we
quantitatively correlated these results with tumor location and
Gleason grade group.

MATERIALS AND METHODS
Robust mpMRI data from 90 patients with MRI-guided biopsyproven prostate cancer were obtained from the SPIE-AAPMNCI Prostate MR Classification Challenge (23, 24). All images
were acquired using two different types of Siemens 3-Tesla MR
scanners (the Magnetom Trio and Skyra) without an endorectal
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FIGURE 1 | Representative images of a dominant intraprostatic lesion contoured on an T2W image, ADC map, and Ktrans map (from left to right). The axial T2W
images were carefully scrutinized along with those in the coronal, and sagittal planes (not shown) to confirm the presence of a hypodense lesion corresponding to the
location of the DIL annotated by an experienced radiologist. In the axial T2W image above, a hypointense lesion is demonstrated in the right peripheral zone. This
same area was then assessed for values that were lower and higher than the surrounding normal prostate tissue in the rigidly-registered axial ADC and Ktrans maps,
respectively. Of note, areas of hypervascularity outside of the contoured region in the Ktrans map shown above were assumed to represent normal vasculature within
the central zone of the prostate gland, as a corresponding area suspicious for cancer was not visualized in either the T2W image or the ADC map.

TABLE 1 | Definitions of contour evaluation metrics.
Definitions
Hausdorff distance (HD): The distance from one point in a subset to the closest point in another subset.
dH = max[sup inf d (x, y) , sup inf d (x, y)]
Mean distance to agreement (MDA): The average of the Hausdorff distances within a defined metric space.
Dice coefficient: Measure of the degree of overlap between sample sets, with a value of 1.0 representing complete overlap (range: 0–1.0).
DICE =

T
B
2*A
A+B

Jaccard index: Comparison of the similarity and diversity of sample sets, with a value of 1.0 representing unity (range 0–1.0).
Jaccard =

T
B
A
T
A+B−A
B

relationship in which case a Pearson correlation may have been
more appropriate.

TABLE 2 | Hausdorff distance (95%), Mean distance to agreement, Dice
coefficient, Jaccard index, and Spearman-rank order by tumor location.
Location

RESULTS

T2-ADC

The DILs were located in the anterior fibromuscular stroma,
central zone, peripheral zone, and transition zone in 35.2, 5.6,
32.4, and 25.4% of patients, respectively. Gleason grade groups 1–
5 represented 30.3, 39.4, 17.2, and 13.1% of the study population,
respectively (with group grades 4 and 5 analyzed together).
The mean contour volumes for the T2W images, and the ADC
and Ktrans maps were 2.14 ± 2.1, 2.22 ± 2.2, and 1.84 ±
1.5 mL, respectively. Ktrans values were indistinguishable between
cancerous regions and normal prostatic tissue for 19 patients.
The Dice coefficient and Jaccard index were 0.74 ± 0.13, 0.60
± 0.15 for T2W-ADC, and 0.61 ± 0.16, 0.46 ± 0.16 for T2WKtrans . For the voxel-based portion of the study, the Spearman
correlations were 0.20 ± 0.20 for T2W-ADC and 0.13 ± 0.25
for T2W-Ktrans .
Tables 2, 3 summarize the Spearman correlation, Dice
coefficient, Jaccard index, as well as the HD and MDA by DIL
location and Gleason grade groups, respectively.
The DIL was separately contoured for 19 patients by a second
radiation oncologist to assess for interobserver variability (these
results were not analyzed with respect to Gleason Grade and

Frontiers in Oncology | www.frontiersin.org

T2-Ktrans

AFS

Peripheral

Cent/Tran

Total

HD

4.46 ± 1.69

4.11 ± 1.39

4.36 ± 2.43

4.32 ± 1.89

MDA

0.96 ± 0.53

0.94 ± 0.45

1.00 ± 0.77

0.97 ± 0.60

Dice

0.73 ± 0.12

0.69 ± 0.16

0.74 ± 0.16

0.74 ± 0.13

Jaccard

0.59 ± 0.14

0.55 ± 0.17

0.61 ± 0.18

0.60 ± 0.15

Spearman

0.15 ± 0.16

0.26 ± 0.26

0.18 ± 0.13

0.20 ± 0.20

HD

6.46 ± 2.42

5.77 ± 2.82

6.57 ± 4.18

6.21 ± 3.25

MDA

1.65 ± 0.65

1.53 ± 0.97

1.63 ± 1.13

1.59 ± 0.95

Dice

0.61 ± 0.15

0.59 ± 0.17

0.61 ± 0.19

0.61 ± 0.16

Jaccard

0.45 ± 0.16

0.44 ± 0.17

0.46 ± 0.18

0.46 ± 0.16

Spearman

0.18 ± 0.22

0.06 ± 0.26

0.19 ± 0.27

0.13 ± 0.25

Cent/Tran, central/transition; AFS, anterior fibromuscular stroma.

location). For this second set of contours, the Dice coefficient was
0.51 ± 0.19 for T2W-ADC and 0.42 ± 0.13 for T2W-Ktrans . A
comparison between the Dice and Jaccard coefficients, MDA, and
HD for the 19 patients contoured by the two different physicians
is shown in Figure 2.
Table 4 shows the mean, minimum, and maximum pixel
values within the ADC and Ktrans contours of the 90 patients split
according to the Gleason grade group. The results of grade groups
4 and 5 were combined together due to the smaller sample sizes.
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has demonstrated clear benefits in biochemical progressionfree survival across multiple randomized controlled studies.
Unfortunately, biochemical recurrence rates can exceed 25%
at 10 years necessitating further salvage therapy, which can
adversely affect quality of life. Up to 90% of local recurrences
after conventional radiation therapy have been shown to occur
at the site of the DIL (4, 26). This coupled with the tremendous
technological advancements in diagnostic imaging (27) and
modern radiation therapy techniques such as treatment under
image-guidance (28–30), has led to emerging interest in more
accurately targeting the intraprostatic lesion and delivering a
further boost to the dominant site of disease.
While the majority of these efforts have been realized using
intensity-modulated radiation therapy (7, 9, 11, 31–33), studies
have also included dose-escalation using brachytherapy with
biologically equivalent doses of around 200 Gy to the DIL (6, 34–
36), and more recently with stereotactic body radiotherapy using
a simultaneous integrated boost technique (14, 32, 37, 38).

The mean ADC contoured pixel values ranged from 964.14 to
1007.74 mm2 /s among different groups while the Ktrans values
ranged from 3.27 to 6.21 min−1 .

DISCUSSION
Current national guidelines recommend dose-escalated radiation
therapy to the entire intact prostate gland for men receiving
definitive radiation therapy for prostate cancer. This approach

TABLE 3 | Hausdorff distance (95%), Mean distance to agreement, Dice
coefficient, Jaccard index, and Spearman-rank order by Gleason grade group.
Gleason grade group
T2-ADC

HD

1

2

3

4, 5

4.33 ± 2.24 4.21 ± 1.96 4.20 ± 1.26 4.61 ± 1.28

MDA

0.94 ± 0.68 0.96 ± 0.61 0.94 ± 0.37 1.03 ± 0.57

Dice

0.73 ± 0.15 0.73 ± 0.13 0.71 ± 0.14 0.70 ± 0.21

Jaccard

0.59 ± 0.15 0.59 ± 0.15 0.56 ± 0.15 0.57 ± 0.22

Spearman

0.21 ± 0.16 0.25 ± 0.20 0.20 ± 0.19 0.04 ± 0.19

T2-Ktrans HD
MDA

Clinical Outcomes of Radiation Therapy
Boost to the DIL

6.07 ± 3.53 5.89 ± 2.87 6.07 ± 2.44 7.51 ± 4.62
1.65 ± 1.29 1.50 ± 0.68 1.40 ± 0.66 2.02 ± 1.33

Dice

0.60 ± 0.22 0.60 ± 0.14 0.65 ± 0.12 0.57 ± 0.22

Jaccard

0.46 ± 0.21 0.44 ± 0.15 0.50 ± 0.12 0.43 ± 0.22

Spearman

0.15 ± 0.24 0.10 ± 0.23 0.12 ± 0.32 0.15 ± 0.27

Early results have demonstrated efficacy with low acute
and late toxicities with either treatment approach. A recent
systematic review of dose-escalated radiation therapy to the DIL

FIGURE 2 | Dice, Jaccard, Mean Distance to Agreement (MDA), and 95% Hausdoff Distance (HD) for 19 patients contoured by the two different physicians. One
physician’s contour comparisons (i.e., T2-ADC vs. T2-Ktrans ) are denoted by blue and orange, respectively, while the other physician’s contour comparisons (i.e.,
T2-ADC vs. T2-Ktrans ) are denoted by gray and yellow, respectively. The data suggests strong dependence on physician performance and relatively high
interobserver variability.

Frontiers in Oncology | www.frontiersin.org
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TABLE 4 | Mean, minimum, and maximum contoured pixel values for ADC and Ktrans .
Gleason grade group

Number of patients (%)

ADC Mean

ADC min

ADC max

mm/s

mm/s

mm/s

ADC SD

Ktrans mean

Ktrans min

Ktrans max

Min−1

Min−1

Min−1

Ktrans SD

1

30.3

964.14

661.55

1247.63

136.70

3.27

0

13.54

2

39.4

988.43

822.13

1380.78

130.65

3.81

0

10.54

3.52
3.19

3

17.2

1007.74

656.63

1334.02

163.89

6.21

0

17.29

4.92

4+5

13.1

999.62

770.11

1806.99

251.47

3.56

0

16.28

5.37

SD, standard deviation.

compartment models such as intravoxel incoherent motion and
vascular, extracellular, and restricted diffusion for cytometry
in tumors. It was difficult to achieve an optimal balance of
spatial and temporal resolution of the DCE scans in the pelvic
region. In the past decade, several models have been recruited
in pharmacokinetic analysis of clinical trial data and animal
studies to calculate the plasma volume fraction, extravascular
and extracellular volume fraction, and Ktrans (42–45). However,
few have examined whether the models are appropriate to the
data (46, 47) and the variances and co-variances of parametric
estimates, as well as the biases introduced by systematic errors,
is generally lacking. Model selection, which is a potential
solution since it defines the region of leaky microvasculature,
a tumor signature, allows delineating different tumor regions
and the temporal evolution of the local model and producing
approximately unbiased estimate of vascular parameters that
are relatively independent of variation in the details of image
acquisition and equipment (48).

demonstrated that the average grade 3+ gastrointestinal and
genitourinary late toxicity was ∼2–3% for intensity-modulated
radiation therapy, 6–10% for stereotactic body radiotherapy, and
2–6% for brachytherapy (39). The median 5-years biochemical
progression-free survival was reported to be 85%. However,
the study population included patients of all risk groups with
heterogenous use of androgen deprivation therapy. These factors
need to be taken into consideration when interpreting the results
of these studies.

mpMRI as a Tool for Target Volume
Delineation
mpMRI demonstrates high sensitivity and specificity in the
diagnosis and staging of prostate cancer, and its utility in this
context has been extensively investigated (40, 41). However, its
use as a tool in target volume delineation for the purposes
of radiation treatments has not been adequately elucidated.
Several barriers exist to incorporating mpMRI to define adequate
radiation treatment volumes, one of the most significant being
a lack of sufficient data to determine which mpMRI sequence is
most accurate in defining the DIL. Groenendaal et al. developed
a logistic regression model on DCE and DWI images to
predict tumor presence and validated on whole-mount section
histopathological images for 12 patients. The model achieved
a receiver operating characteristic curve of 0.70 (41). However,
the study was limited to peripheral zone and low Gleason score
lesions (6 and 7). In addition, each image modality reflects
different biological characteristics and may be individually
inconsistent in tumor delineation particularly at the voxel level. It
is unclear whether a combination of MR sequences would confer
any advantage compared to a single mpMRI sequence when
contouring the DIL, especially with respect to clinical outcomes
such as biochemical control.
Considering the technical variability and lack of consensus
on ADC and Ktrans values for intraprostatic lesions, we did
not use automatic threshold values for segmentation. ADC and
Ktrans values can have significant variations across different
scanning protocols and MR scanners which makes quantitative
analysis difficult. The monoexponential ADC model was used
to describe the water diffusion behavior in this study. The b
value selection as well as the duration and strength of diffusion
sensitizing gradients could have impact on the ADC value. And
the ADC values depended on many factors including cell density,
size, shape, permeability, and perfusion effects. The complex
diffusion dynamics of biological tissue required more advanced

Frontiers in Oncology | www.frontiersin.org

Tumor Size and Location Are Important
Considerations
Smaller lesions pose a challenge to using mpMRI to accurately
and reproducibly target the DIL as imaging precision is known to
become less accurate as volume decreases. This was previously
reported by Groenendaal et al. (49), citing the impact of
noise and geometrical distortions induced by MRI machines
in complicating the validity of functional MRI techniques for
smaller volumes. In this study, the mean contour volume for the
T2W images, and the ADC and Ktrans maps were 2.14 ± 2.1, 2.22
± 2.2, and 1.84 ± 1.5 mL, respectively. It is reasonable to assume
that with such small volumes, even slight differences in contours
can result in significantly altered results.
The location of the DIL also plays a role in precise target
delineation with mpMRI as lesions involving different zones
of the prostate gland can present unique challenges. Prostate
cancer most commonly involves the peripheral zone of the gland
and appears as a region of homogenous low-signal intensity
on T2W. Tumor involving of the central gland can be more
difficult to discern (e.g., due to benign prostatic hyperplasia),
but cross-observer consensus can be reached in up to 80% of
cases (50). Similarly, Ktrans does not reliably differentiate prostate
cancer from benign prostatic hyperplasia within the central
zone of the prostate gland due to similarities in microvascular
density exhibited by both conditions. In fact, Ktrans values were

5
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This would, in theory, allow the entire DIL to be included in the
radiation boost volume reducing the probability of a marginal
miss especially with an adequately designed margin. The value
of adding information provided by Ktrans maps to the BSV
remains investigational at this time as this mpMRI sequence
was not reliably and consistently detectable as elaborated on
above. A larger study population and a community consensus
on quantitative analysis of Ktrans may be warranted prior to its
systematic incorporation into tumor delineation.

indistinguishable between tumor foci and the normal prostate
gland for 19 patients in this study suggesting that the value of
this mpMRI sequence may be limited to more peripheral lesions.

Quantitative Correlation Between the DIL
and Tumor Location
To evaluate the quantitative correlation between contours on
each imaging modality and its statistical dependence on tumor
location and Gleason grade group, the Hausdorff distance (HD),
mean distance to agreement (MDA), Dice coefficient, and Jaccard
index were calculated between the contours for each pair of
MR sequences (i.e., T2W vs. ADC, T2W vs. Ktrans , and ADC
vs. Ktrans ). Table 2 summarizes the results of the statistical
analysis based on tumor location. Between T2W-ADC and T2WKtrans , the Dice coefficient was 0.74 ± 0.13 and 0.61 ± 0.16,
respectively, and the Jaccard index was 0.60 ± 0.15 and 0.46
± 0.16, respectively. This suggests that there was a relatively
high level of overlap between the contours regardless of tumor
location, and that the contours were slightly more similar than
they were divergent. Furthermore, the results were consistently
better between T2W-ADC vs. T2W-Ktrans which may reflect the
fact that T2W images provide anatomical information whereas
Ktrans maps reflect the permeability of regional vasculature;
consequently, although we expect to appreciate a certain level of
correlation between the two MR sequences, it is understandable
that a more substantial overlap between the contours was not
observed. Conversely, the voxel-based Spearman correlation
was 0.21 ± 0.18 and 0.13 ± 0.25, respectively, suggesting that
the strength of the association between the contours was not
very robust.

Interobserver Variability
Nineteen cases were contoured by two radiation oncologists
in an effort to assess for interobserver variability. There was a
large difference in the Dice coefficient between the contoured
DILs (23 and 19% for T2W-ADC and T2W-Ktrans , respectively).
This is not surprising as significant interobserver variability is
a known limitation in the interpretation of mpMRI images.
As previously mentioned, the small volumes of the contours
in this study (mean volumes ranging from 1.84 to 2.14 mL)
may have amplified even the smallest of differences in tumor
delineation, and whether these marginal statistical discrepancies
would translate into meaningful differences in clinical outcome
is debatable. Furthermore, it would be impractical for more
than one radiation oncologist to delineate the DIL in clinical
practice. A more pragmatic approach would be to develop an
expert consensus guideline on DIL delineation coupled with
suggestions for optimal clinical target volume margins to ensure
adequate coverage.

Contoured Pixel Values
The mean, minimum, and maximum contoured pixel values for
ADC and Ktrans are tabulated in Table 4. This information is
intended as a baseline threshold recommendation for automatic
segmentation of ADC and Ktrans maps based on Gleason grade
group. The contours used to obtain this data were delineated
by the original physician on 90 patients. Of note, the Ktrans
mean pixel value is relatively high compared to reported tumor
regions in previous studies (40, 51–53). Ktrans images used in
this study were procured by a method explained in Huisman
et al. (54), which results with differing pixel values than other
commonly used methods. Since this study has shown that there is
a large variation of ADC and Ktrans values in each Gleason grade
group, future work is needed to recommend specific thresholds
for automatic delineation with the verification of whole-mount
histopathologic section findings.

Quantitative Correlation Between the DIL
and Gleason Grade Group
Table 3 summarizes the results of the statistical analysis based
on Gleason grade group. Between T2W-ADC and T2W-Ktrans ,
the overall Dice coefficient and Jaccard index were identical to
the results based on tumor location. Furthermore, the voxelbased Spearman correlation between T2W-ADC was similarly
low, especially for Gleason grade groups 4 and 5 (0.04 ± 0.19)
suggesting a very poor correlation between anatomical imaging
and diffusion-weighted and perfusion-based imaging in poorlydifferentiated prostate cancer. Again, the results were consistently
better between T2W-ADC vs. T2W-Ktrans .

Incorporating a Boolean Sum Volume (BSV)
to Better Delineate the DIL

Study Limitations

As previously mentioned, the Spearman correlation between
tumor location and Gleason grade group for the MR sequences
was rather weak. This was particularly so between the T2W
images and ADC maps for lesions with Gleason grade groups 4
and 5 (although lower Gleason grade group did not necessarily
predict for a higher correlation). This data would suggest that
constructing a BSV that incorporates T2W images and ADC
maps may be reasonable for delineating the DIL on mpMRI, as
the BSV would adequately represent radiographic disease that is
both anatomically- and functionally-defined. This is supported
by the fact that the level of correlation between T2W images
and ADC maps was relatively high but far from reaching unity.
Frontiers in Oncology | www.frontiersin.org

The limitations of this study include its retrospective design,
inherent inconsistencies between functional MR images (e.g.,
different institutional imaging protocols such as contrast inject
rate, variations in patient body mass index, and differences
in spatial and temporal resolution), lack of histopathological
validation, maximum b-value of 800 in calculating the ADC
map, and tumor delineation by only two radiation oncologists.
A prospectively designed study using standardized imaging with
up-to-date protocols and contouring by a team of experienced
radiation oncologists allowing for interobserver variability would
strengthen the validity of these results.
6

July 2019 | Volume 9 | Article 616

Lee et al.

Contour Analysis of DILs on mpMRI

CONCLUSIONS

ETHICS STATEMENT

Using mpMRI to delineate a target volume for a radiation boost
is an emerging area of interest and one that may improve clinical
outcomes without increasing the toxicity associated with external
beam radiation therapy. The intraprostatic lesions contoured
on T2W images had a high level of agreement with those
contoured on ADC maps, but there was little to no quantitative
correlation of these results with tumor location and Gleason
grade group. As shown in the study, there have been many
technical hurdles to be solved for precision radiotherapy to
target the tumor based on physiological imaging and understand
its corresponding treatment outcome. A BSV incorporating
all available MR sequences may be reasonable at the current
stage in delineating the DIL boost volume for clinical practice.
A larger study population and a community consensus on
quantitative analysis of Ktrans is warranted prior to its systematic
incorporation into tumor delineation.
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